For your adult patients with CKD associated with T2D
†If serum potassium levels are >4.8 to 5.0 mEq/L, initiation may be considered with additional potassium monitoring within the first 4 weeks based on clinical judgment and serum potassium levels.
If eGFR has decreased by more than 30% compared to previous measurement, maintain 10-mg dose.
For patients who are unable to swallow whole tablets, KERENDIA may be crushed and mixed with water or soft foods such as applesauce immediately prior to use and administered orally.13
Adult patients with CKD associated with T2D and albuminuria may be appropriate candidates for treatment with KERENDIA. KERENDIA was studied across a broad range of CKD severity.
Between the 2 phase 3 trials (FIGARO-DKD and FIDELIO-DKD), KERENDIA has been studied in more than 13,000 adult T2D patients across a broad range of CKD severity. The FIGARO-DKD trial studied patients with CKD associated with T2D, defined as either having a UACR of 30 to <300 mg/g and an eGFR of 25 to 90 mL/min/1.73 m2, or as having a UACR of ≥300 mg/g and an eGFR of ≥60 mL/min/1.73 m2. The FIDELIO-DKD trial studied patients with CKD associated with T2D, defined as either having a UACR of 30 to <300 mg/g, eGFR 25 to <60 mL/min/1.73 m2 and diabetic retinopathy, or as having a UACR of ≥300 mg/g and an eGFR of 25 to <75 mL/min/1.73 m2.View references
CKD=chronic kidney disease; eGFR=estimated glomerular filtration rate; T2D=type 2 diabetes; UACR=urine albumin-to-creatinine ratio.
CKD=chronic kidney disease; eGFR=estimated glomerular filtration rate; T2D=type 2 diabetes.
KERENDIA is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
Hyperkalemia: KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serum potassium is >5.0 mEq/L
Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium
Please read the Prescribing Information for KERENDIA.